Company intelligence / Profile preview
TuHURA Biosciences, Inc.
Tampa, Florida, United Statestuhurabio.com ↗
- Ownership
- Public · HURA
- Employees
- ~19
- Development stage
- Phase 3
01
Overview
TuHURA’s lead candidate IFx‑2.0 is a first-in-class innate immune response agonist designed to overcome primary resistance to checkpoint inhibitors. A single randomized placebo-controlled Phase 3 registration trial as adjunctive therapy with Keytruda® in advanced/metastatic Merkel Cell Carcinoma is set to begin in early/mid‑2025. The company also advances bi-specific ADCs/PDCs targeting MDSCs and plans expansion into additional indications such as aggressive lymphomas. Early clinical data have not yet been published from the new pipeline post-merger.[1][6]
- Therapeutic areas
- Oncology
- Modalities
- Personalized innate immune agonists (e.g., IFx technology)Bi-specific antibody drug conjugates (ADCs)Peptide drug conjugates (PDCs)Cancer vaccinesmRNA-based therapies[1][2][5][7]
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships announced yet but company states intent to seek collaborations/licensing deals with large pharmaceutical or biotech companies.[2]Has entered exclusivity/right-of-first-offer agreements regarding Kineta's KVA12123 asset.[10]
04
Financials
- Market cap
- $102.6M
- Total revenue
- $0
- Enterprise value
- $102M
Beyond the preview
Go deeper on TuHURA Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TuHURA Biosciences, Inc..